循环肿瘤细胞检测ALK重排用于晚期NSCLC无创纵向管理的前瞻性多中心验证
该多中心前瞻性观察研究纳入203例IIIB/IV期NSCLC患者(81例ALK阳性、122例ALK阴性),评估循环肿瘤细胞(CTC)作为组织ALK分析替代标志物的价值。基线时CTC免疫细胞化学检测ALK重排与组织检测高度一致(敏感性94.4%、特异性89.4%),但FISH分析性能较低。CTC基线水平或动态变化与总生存或无进展生存无显著关联。
要点
- CTC免疫细胞化学检测ALK重排与组织检测高度一致,可作为组织活检的补充工具。
- CTC的FISH分析敏感性仅35.6%、特异性56.9%,性能低于免疫细胞化学。
- ALK阳性患者中CTC基线水平或动态变化与OS或PFS无显著关联。
核心结论
- CTC可作为组织活检的补充工具用于检测ALK重排。
- CTC纵向分析有望用于该人群的实时监测和改善分子指导治疗。
研究设计与样本
- 多中心、前瞻性观察研究(NCT02372448),纳入法国九家中心的203例IIIB/IV期NSCLC患者。
- 81例经免疫组织化学或FISH检测为ALK阳性,122例经石蜡包埋组织标本检测为ALK阴性。
- 在基线以及ALK抑制剂启动后6周和12周或疾病进展时采集血样。
- 采用过滤法富集后,用免疫细胞化学和FISH分析CTC的ALK基因重排。
主要发现
- 基线时组织与CTC免疫细胞化学检测ALK重排高度一致:敏感性94.4%,特异性89.4%。
- FISH分析性能较低:敏感性35.6%,特异性56.9%。
- ALK阳性NSCLC患者中,CTC基线水平或动态变化与总生存无显著关联(HR=0.59,95%CI:0.24-1.5,p=0.244)。
- ALK阳性NSCLC患者中,CTC基线水平或动态变化与无进展生存无显著关联(HR=0.84,95%CI:0.44-1.6,p=0.591)。
临床怎么用
- 在组织不足或无法获取组织时,可考虑用CTC免疫细胞化学检测ALK重排作为补充。
- CTC FISH分析敏感性低,不宜单独用于ALK重排检测。
- CTC纵向分析可用于ALK阳性NSCLC患者的实时监测,但需进一步验证其临床效用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Patients with advanced-stage NSCLC whose tumors harbor an ALK gene rearrangement benefit from treatment with multiple ALK inhibitors (ALKi). Approximately 30% of tumor biopsy samples contain insufficient tissue for successful ALK molecular characterization. This study evaluated the added value of analyzing circulating tumor cells (CTCs) as a surrogate to ALK tissue analysis and as a function of the response to ALKi. METHODS: We conducted a multicenter, prospective observational study (NCT02372448) of 203 patients with stage IIIB/IV NSCLC across nine French centers, of whom 81 were ALK positive (immunohistochemistry or fluorescence in situ hybridization [FISH]) and 122 ALK negative on paraffin-embedded tissue specimens. Blood samples were collected at baseline and at 6 and 12 weeks after ALKi initiation or at disease progression. ALK gene rearrangement was evaluated with CTCs using immunocytochemistry and FISH analysis after enrichment using a filtration method. RESULTS: At baseline, there was a high concordance between the detection of an ALK rearrangement in the tumor tissue and in CTCs as determined by immunocytochemistry (sensitivity, 94.4%; specificity 89.4%). The performance was lower for the FISH analysis (sensitivity, 35.6%; specificity, 56.9%). No significant association between the baseline levels or the dynamic change of CTCs and overall survival (hazard ratio = 0.59, 95% confidence interval: 0.24-1.5, p = 0.244) or progression-free survival (hazard ratio = 0.84, 95% confidence interval: 0.44-1.6, p = 0.591) was observed in the patients with ALK-positive NSCLC. CONCLUSIONS: CTCs can be used as a complementary tool to a tissue biopsy for the detection of ALK rearrangements. Longitudinal analyses of CTCs revealed promise for real-time patient monitoring and improved delivery of molecularly guided therapy in this population.
引用
- Ilié M, Mazières J, Chamorey E, et al. Prospective Multicenter Validation of the Detection of ALK Rearrangements of Circulating Tumor Cells for Noninvasive Longitudinal Management of Patients With Advanced NSCLC. J Thorac Oncol. 2021. PMID: 33545389. doi:10.1016/j.jtho.2021.01.1617
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。